Cross-source evidence timeline

Glatiramer acetate research timeline

Follow 65 selected, directly cited source records from December 20, 1996 through November 16, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

65Selected records
16Source years
3Evidence lanes
November 16, 2026Latest source date

Source year

2026

7 records
  1. Clinical trials

    ClinicalTrials.gov record NCT05344469↗

    PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  2. Literature metadata

    Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.↗

    PubMed lists PMID 27880972 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2016-11-24 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.↗

    PubMed lists PMID 41705515 in Multiple sclerosis (Houndmills, Basingstoke, England) as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair.↗

    PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Randomized study combining interferon and glatiramer acetate in multiple sclerosis.↗

    PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Drugs@FDA application ANDA213382↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗

  7. Regulatory

    Drugs@FDA application ANDA214022↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗

Source year

2025

5 records
  1. Regulatory

    Drugs@FDA application ANDA214741↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.↗

  2. Literature metadata

    Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.↗

    PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.↗

    PubMed lists PMID 35563884 in Cells as Journal Article, Systematic Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2022-05-07 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Drugs@FDA application ANDA208468↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03193866↗

    PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2024

4 records
  1. Regulatory

    Drugs@FDA application ANDA203857↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA206873↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.↗

  3. Literature metadata

    Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?↗

    PubMed lists PMID 23203082 in International journal of molecular sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-11-09 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Interferon beta and glatiramer acetate therapy.↗

    PubMed lists PMID 23264098 in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2022

4 records
  1. Literature metadata

    Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?↗

    PubMed lists PMID 35493825 in Frontiers in neurology as Journal Article, Review, with publication-date metadata of 2022-04-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.↗

    PubMed lists PMID 22989378 in BMC neurology as Controlled Clinical Trial, Journal Article, with publication-date metadata of 2012-09-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.↗

    PubMed lists PMID 23795716 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2013-06-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.↗

    PubMed lists PMID 26458034 in JAMA neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-12 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

6 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01067521↗

    PeptideScanner retained ClinicalTrials.gov record NCT01067521 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02499900↗

    PeptideScanner retained ClinicalTrials.gov record NCT02499900 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00176592↗

    PeptideScanner retained ClinicalTrials.gov record NCT00176592 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  4. Literature metadata

    Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.↗

    PubMed lists PMID 23589190 in Journal of neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-04-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00937157↗

    PeptideScanner retained ClinicalTrials.gov record NCT00937157 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  6. Literature metadata

    Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.↗

    PubMed lists PMID 32897569 in Acta neurologica Scandinavica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2020-10-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

3 records
  1. Literature metadata

    Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use.↗

    PubMed lists PMID 30775037 in Multiple sclerosis international as Journal Article, Review, with publication-date metadata of 2019-01-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate.↗

    PubMed lists PMID 31526436 in Die Pharmazie as Journal Article, Review, with publication-date metadata of 2019-08-01 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00203021↗

    PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2019

3 records
  1. Literature metadata

    Glatiramer acetate: A complex drug beyond biologics.↗

    PubMed lists PMID 30902653 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, Review, with publication-date metadata of 2019-03-19 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.↗

    PubMed lists PMID 29241378 in Expert opinion on drug delivery as Journal Article, Review, with publication-date metadata of 2017-12-22 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Glatiramer Acetate: from Bench to Bed and Back.↗

    PubMed lists PMID 30905097 in The Israel Medical Association journal : IMAJ as Journal Article, Review, with publication-date metadata of 2019-03 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

9 records
  1. Literature metadata

    Spasticity in multiple sclerosis and role of glatiramer acetate treatment.↗

    PubMed lists PMID 26445705 in Brain and behavior as Journal Article, Review, with publication-date metadata of 2015-07-14 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.↗

    PubMed lists PMID 27473139 in Neurology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-07-29 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT02153723↗

    PeptideScanner retained ClinicalTrials.gov record NCT02153723 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-11-05, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  4. Regulatory

    Federal Register notice 2018-15735↗

    The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00078338↗

    PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT01569451↗

    PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  7. Literature metadata

    Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate.↗

    PubMed lists PMID 27363291 in Pediatric neurology as Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-05-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Regulatory

    Drugs@FDA application ANDA206921↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT00856635↗

    PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2017

4 records
  1. Regulatory

    Drugs@FDA application ANDA091646↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA206936↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00947752↗

    PeptideScanner retained ClinicalTrials.gov record NCT00947752 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-03-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00239993↗

    PeptideScanner retained ClinicalTrials.gov record NCT00239993 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2016

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00451204↗

    PeptideScanner retained ClinicalTrials.gov record NCT00451204 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-06-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  2. Regulatory

    Federal Register notice 2016-08682↗

    The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01874145↗

    PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2015

7 records
  1. Regulatory

    Federal Register proposed rule 2015-32246↗

    The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.↗

  2. Literature metadata

    Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).↗

    PubMed lists PMID 26671082 in Journal of the neurological sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-08 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.↗

    PubMed lists PMID 22449210 in Expert review of neurotherapeutics as Journal Article, Review, with publication-date metadata of 2012-04 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    The use of interferon Beta and glatiramer acetate in multiple sclerosis.↗

    PubMed lists PMID 23709209 in Seminars in neurology as Journal Article, Review, with publication-date metadata of 2013-05-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01317004↗

    PeptideScanner retained ClinicalTrials.gov record NCT01317004 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-06-22, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  6. Regulatory

    Drugs@FDA application ANDA090218↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT00451451↗

    PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2014

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01534182↗

    PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00211887↗

    PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01216072↗

    PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2013

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01167426↗

    PeptideScanner retained ClinicalTrials.gov record NCT01167426 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-10-17, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01071083↗

    PeptideScanner retained ClinicalTrials.gov record NCT01071083 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-09-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2012

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00811395↗

    PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00475865↗

    PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00666224↗

    PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

2011

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00337779↗

    PeptideScanner retained ClinicalTrials.gov record NCT00337779 at 2026-11-16T17:42:50.457Z. Its registry update date was 2011-10-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Source year

1996

1 record
  1. Regulatory

    Drugs@FDA application NDA020622↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients.↗